{"organizations": [], "uuid": "06c7f3720901d5e7f3c8cec51e32d885ac075577", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-armo-biosciences-announces-positiv/brief-armo-biosciences-announces-positive-outcome-of-first-interim-analysis-in-sequoia-phase-3-pancreatic-cancer-study-idUSFWN1R80IB", "country": "US", "domain_rank": 408, "title": "BRIEF-Armo Biosciences Announces Positive Outcome Of First Interim Analysis In Sequoia Phase 3 Pancreatic Cancer Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.097, "site_type": "news", "published": "2018-03-26T20:21:00.000+03:00", "replies_count": 0, "uuid": "06c7f3720901d5e7f3c8cec51e32d885ac075577"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-armo-biosciences-announces-positiv/brief-armo-biosciences-announces-positive-outcome-of-first-interim-analysis-in-sequoia-phase-3-pancreatic-cancer-study-idUSFWN1R80IB", "ord_in_thread": 0, "title": "BRIEF-Armo Biosciences Announces Positive Outcome Of First Interim Analysis In Sequoia Phase 3 Pancreatic Cancer Study", "locations": [], "entities": {"persons": [{"name": "terim", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-armo biosciences announces positive outcome of first interim analysis", "sentiment": "negative"}, {"name": "reuters) - armo biosciences inc", "sentiment": "neutral"}, {"name": "dmc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "armo biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - Armo Biosciences Inc:\n* ARMO BIOSCIENCES ANNOUNCES POSITIVE OUTCOME OF FIRST INTERIM ANALYSIS IN SEQUOIA PHASE 3 PANCREATIC CANCER STUDY\n* ARMO BIOSCIENCES INC - DMC RECOMMENDED THAT STUDY CONTINUE WITHOUT MODIFICATION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T20:21:00.000+03:00", "crawled": "2018-03-27T11:38:15.029+03:00", "highlightTitle": ""}